- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03654040
Liver Transplantation With Tregs at UCSF (LITTMUS-UCSF)
A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The researchers in this study plan to enroll 9 participants. Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 to 500 x 10^6 total cells.
Participants who successfully withdraw from all immunosuppression (IS) will undergo a research biopsy at 52 weeks following IS discontinuation to determine whether they meet the primary efficacy outcome of operational tolerance. Participants determined to be operationally tolerant will be followed until 104 weeks following IS discontinuation. Participants who fail drug withdrawal after 52 weeks but before 104 weeks will be followed until week 104 or 12 weeks after resuming immunosuppression, whichever is longer.
Participants who do not successfully withdraw from all IS will complete 104 weeks of High Intensity Safety Follow-up after failing immunosuppression withdrawal.
*** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases and the Immune Tolerance Network do not recommend the discontinuation of immunosuppressive therapy for recipients of cell, organ, or tissue transplants outside of physician-directed, controlled clinical studies. Discontinuation of prescribed immunosuppressive therapy can result in serious health consequences and should only be performed in certain rare circumstances, upon the recommendation and with the guidance of your health care provider.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Eligibility:
Recipient:
Individuals must meet all of the following criteria to be eligible for this study:
- Able to understand and provide informed consent
- End-stage liver disease and listed for a living or deceased-donor primary solitary liver transplant
- Agreement to use contraception
- For candidates with a history of hepatitis C virus (HCV), completed treatment for HCV, maintaining a sustained viral response of ≥24 weeks duration by the day of transplant
- Positive Epstein-Barr virus (EBV) antibody test, and
Immunizations are up-to-date based on the Advisory Committee on Immunization Practices (ACIP) recommendations for individuals with Liver Disease and Adult Vaccination, unless the investigator determines that administering a recommended immunization is not in the patient's best interest.
Living Donor:
Living donors must meet all of the following criteria to be eligible for this study:
- Able to understand and provide informed consent
- Meets site-specific clinical donor eligibility requirements
- Meets donor eligibility manufacturing requirements within 7 days before or after the blood collection for manufacturing, and
- Willingness to donate appropriate biologic samples.
Deceased Donor:
Deceased donors must meet the following criteria for their recipients to remain eligible:
- Meets site-specific clinical donor eligibility requirements and
- Meets donor eligibility manufacturing requirements.
Note:
- There are several stages to this study.
- Eligibility is evaluated at many time points during the study to assess whether a participant is safe to proceed to the next study stage.
Exclusion Criteria:
Recipient:
Individuals who meet any of the following criteria will not be eligible for this study:
- History of previous organ, tissue or cell transplant
- For cytomegalovirus (CMV) antibody negative recipients, a (CMV) antibody positive donor
- Known contraindication to cyclophosphamide or mesna
- Serologic evidence of human immunodeficiency virus (HIV)-1/2 infection
- The need for chronic anti-coagulation or anti-platelet agents other than aspirin that cannot be safely discontinued for a minimum of 1 week to safely perform a liver biopsy
- End stage liver disease secondary to autoimmune etiology (autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis) or other contraindications to drug withdrawal
- Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up visit schedule
- Any condition that, in the opinion of the investigator, may interfere with study compliance
- History of cardiac disease (ischemic heart disease requiring revascularization, history of or current treatment for dysrhythmia, or evidence of congestive heart failure), unless cleared by a cardiologist
Any past or current medical problems, treatments or findings that are not listed above, which, in the opinion of the investigator, may:
- pose additional risks from participation in the study,
- interfere with the candidate's ability to comply with study requirements, or
impact the quality or interpretation of the data obtained from the study.
- This includes past, present or future enrollment in studies that affect eligibility at the time of everolimus (EVR) conversion
History of malignancy or any concomitant malignancy, except:
- hepatocellular carcinoma,
- completely treated in-situ cervical carcinoma, or
- completely treated basal cell carcinoma.
Chronic use of systemic glucocorticoids or other immunosuppressives, or biologic immunomodulators.
Living Donor:
- There are no exclusion criteria for living donors.
Deceased Donor:
-There are no exclusion criteria for deceased donors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: arTreg
arTreg: alloantigen-reactive T regulatory cells The investigational product is donor alloantigen-reactive regulatory T cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna. Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to <90 x10^6 total cells will be included in intent-to-treat analysis. |
Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10^6 total cells. Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes.
Other Names:
Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen. Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion.
Other Names:
40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
Other Names:
Mesna is administered:
Other Names:
EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant.
Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed.
Once the optimal EVR trough level is achieved,TAC dose will be reduced.
When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen.
EVR doses will be administered/monitored/adjusted over time.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Operationally Tolerant Participants
Time Frame: 52 (± 4 weeks) after the last dose of immunosuppression
|
Operational tolerance is defined as:
|
52 (± 4 weeks) after the last dose of immunosuppression
|
Number and Severity of Adverse Events (AEs) Attributed to the Investigational Product, arTreg
Time Frame: From arTreg infusion through completion of study participation
|
|
From arTreg infusion through completion of study participation
|
Number and Severity of Adverse Events (AEs) Attributed to Supportive Regimen: Leukapheresis, Cyclophosphamide or Mesna
Time Frame: From ≤3 days prior to arTreg infusion through completion of study participation (Up to 3 months)
|
|
From ≤3 days prior to arTreg infusion through completion of study participation (Up to 3 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Develop a Malignancy
Time Frame: Time of enrollment through completion of study participation (Up to 1.8 years)
|
The number of participants that are diagnosed with malignancy, any type.
|
Time of enrollment through completion of study participation (Up to 1.8 years)
|
Incidence of ≥Grade 3 Infections Following arTreg Infusion
Time Frame: From arTreg infusion through completion of study participation
|
Grading: According to the NCI Common Terminology Criteria for Adverse Events Manual [NCI-CTCAE version 5.0, published November 27, 2017].
|
From arTreg infusion through completion of study participation
|
Number of Biopsy-Proven Acute Rejection (AR) and/or Clinical Rejection Events at Any Time After Alloantigen-Reactive Tregs (arTreg) Infusion
Time Frame: From arTreg infusion through completion of study participation
|
Definitions:
|
From arTreg infusion through completion of study participation
|
Severity of Biopsy-Proven Acute Rejection (AR) and/or Clinical Rejection Events at Any Time After Alloantigen-Reactive Tregs (arTreg) Infusion
Time Frame: From arTreg infusion through completion of study participation
|
Intensity of AR and/or clinical rejection events will be graded. Definitions:
|
From arTreg infusion through completion of study participation
|
Number of Chronic Rejection Events at Any Time After Alloantigen-Reactive Tregs (arTreg) Infusion
Time Frame: From arTreg infusion through completion of study participation
|
Diagnosed in accordance with Banff global assessment criteria.
|
From arTreg infusion through completion of study participation
|
Proportion of Participants Who Successfully Discontinue Tacrolimus
Time Frame: Post-transplant through Completion of Study Participation
|
Proportion of participants who, per protocol:
|
Post-transplant through Completion of Study Participation
|
Duration of Operational Tolerance
Time Frame: Post-transplant through Completion of Study Participation
|
Durability of operational tolerance defined as the time from achieving the primary endpoint to immunosuppression (IS) reinitiation or to the end of trial participation.
|
Post-transplant through Completion of Study Participation
|
Collaborators and Investigators
Investigators
- Study Chair: Sandy Feng, MD, PhD, University of California, San Francisco
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Protein Kinase Inhibitors
- MTOR Inhibitors
- Cyclophosphamide
- Everolimus
Other Study ID Numbers
- DAIT ITN074ST
- UM1AI109565 (U.S. NIH Grant/Contract)
- NIAID CRMS ID#: 38481 (Other Identifier: DAIT NIAID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplant
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityNot yet recruitingLiver Metastases | Liver Transplant; Complications | Liver Cancer | Transplant | Transplant; Failure, Liver | Transplant; Complication, Rejection | Transplant Dysfunction
-
University Health Network, TorontoNot yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)TerminatedLiver Transplant | Kidney TransplantUnited States
-
Astellas Pharma Europe Ltd.CompletedLiver Transplant | Kidney TransplantItaly, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
-
Memorial Bahçelievler HospitalCompletedLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Transplant; Complications | Liver Transplant Rejection | Organ Transplant Failure or Rejection | Liver Transplant FailureTurkey
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedLiver Transplant | Kidney TransplantUnited States, Singapore
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
Paragonix TechnologiesEnrolling by invitationLiver Diseases | Liver Transplant Disorder | Liver Dysfunction | Liver Transplant RejectionUnited States
-
PilloxaTerminatedLiver Transplant; Complications | Kidney Transplant; ComplicationsSweden
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Clinical Trials in Organ Transplantation...CompletedLiver Transplant Recipient | Living Donor (of the Respective Liver Transplant Recipient)United States
Clinical Trials on arTreg
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Active, not recruiting